Overview
Global Blood Therapeutics develops and delivers treatments for sickle cell disease. Its core product, Oxbryta (voxelotor), is an oral medicine approved by the FDA for SCD patients as young as 4 years old, and the company conducts research, clinical trials, and regulatory work to bring new therapies to market. Oxbryta works by acting on hemoglobin to reduce red blood cell sickling, supporting healthier blood flow. The company differentiates itself through a focused, disease-specific portfolio and active patient advocacy, prioritizing SCD care and community engagement alongside its R&D efforts. Its goal is to change the treatment paradigm for SCD by expanding options, improving outcomes, and progressing toward additional therapies for patients and families affected by the disease.
Work here?Claim your company
Simplify's take
What believers are saying
- Pfizer closed the $5.4 billion GBT deal, financing development and commercialization.
- GBT still has osivelotor in phase 3 despite the partial clinical hold.
- SCD remains an underserved market, and Pfizer can rapidly commercialize any approved winner.
What critics are saying
- Oxbryta was withdrawn worldwide after death-imbalance findings, destroying trust in 2025.
- Inclacumab failed THRIVE-131 in 2026, eliminating another promised SCD growth driver.
- Osivelotor sits under FDA partial clinical hold, leaving Pfizer with a shrinking pipeline.
What makes Global Blood Therapeutics unique
- GBT built the leading Pfizer sickle-cell franchise, anchored by Oxbryta and follow-ons.
- It owns deep SCD expertise across hemoglobin modulation and P-selectin inhibition programs.
- Pfizer's commercial infrastructure differentiates GBT from smaller biotech rivals.
Help us improve and share your feedback! Did you find this helpful?